Technology Innovation Institute’s Secure Systems Research Centre Partners with World-leading Universities across Groundbreaking Projects
21.4.2021 15:45:00 EEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) has partnered with Khalifa University, Georgia Institute of Technology, Tampere University and University of Applied Sciences and Arts of Southern Switzerland (SUPSI). Secure Systems Research Centre also recently announced that it had partnered with Purdue University.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005624/en/
Dr Shreekant Thakkar, Chief Researcher, Secure Systems Research Centre (SSRC), Technology Innovation Institute (TII) (Photo: AETOSWire)
The announcement of these collaborations is the latest in a series of announcements by Technology Innovation Institute since the first Advanced Technology Research Council board meeting in August 2020. Secure Systems Research Centre is one of the initial seven dedicated research centres at Technology Innovation Institute. The strategic partnerships will advance breakthroughs in the field of secure systems and its sub-disciplines across crucial projects.
The partnership with the UAE’s prestigious Khalifa University spans four major projects, the first of which explores opportunities to use machine learning for exfiltration detection on android smartphones. The second project involves the development of solutions in secure communications for power-constrained wireless mesh networks while the third investigates physical wireless security and routing protocols on drone communications. Finally, the last project looks at physical layer security for diverse unmanned aerial vehicle (UAV)-ground wireless networks. This project seeks to evaluate the vulnerabilities of these networks and propose efficient solutions to mitigate system weakness.
The partnership with Georgia Institute of Technology in the United States encompasses a project that will devise a theory for constructing attack-resilient software that can address real-time constraints in cyber-physical and autonomous systems (CPAS). The research team will demonstrate techniques that enhance the security of CPAS software and platforms, with a focus on drones. The cooperation with Tampere University in Finland comprises of a project related to critical infrastructure security. This project will uncover methods to reduce an attacker’s ability to infiltrate, steal and manipulate data in critical infrastructure. This research has prominent use-cases in areas such as drone deployment, emergency services, infrastructure on demand, and smart city data processing.
The partnership with Switzerland’s SUPSI will explore AI-based secure autonomous navigation on Nano-UAVs, focusing on security, autonomy, and resilience. The team aims to enable secure communication and computation onboard resource-constrained (i.e., computation, memory, power, and payload) cyber-physical systems (CPSs) by leveraging machine learning, deep learning, and advanced artificial intelligence techniques.
Speaking on the partnership announcements, Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre leading the Secure Autonomous Computing work, said: “Our world is more connected – and more vulnerable to cyberattacks. Smart cities, transportation and other critical infrastructure, require the highest levels of defence against these attacks. The partnerships and crucial projects that we have announced with prestigious global institutions will no doubt have far-reaching advancements in secure and resilient autonomous system solutions that encompass platforms, systems software, communications, applications, and data integrity.”
In March 2021, Technology Innovation Institute announced that Secure Systems Research Centre has partnered with Purdue University, a world-renowned US-based public research university, to collaborate on a three-year sophisticated cybersecurity project to ensure unmanned aerial vehicles can be used safely and efficiently in urban operations.
For more information about Technology Innovation Institute (TII) please visit www.tii.ae
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005624/en/
Contact information
Technology Innovation Institute
Haitham Haddadin
Haitham.Haddadin@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom